Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Harnessing advanced data analysis for early detection, prevention and better outcomes
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
For people with relapsed or refractory diffuse large B-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
